A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT01830985. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in a Treat to Target Setting in Subjects With Rheumatoid Arthritis on Disease-Modifying Antirheumatic Drugs
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to evaluate the long-term safety and tolerability of VX-509 in subjects with active rheumatoid arthritis (RA) on DMARD therapy. This study will enroll subjects who completed a previous designated study with VX-509 (e.g., Study VX12-509-103).
Study identification
- NCT ID
- NCT01830985
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 39 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2013
- Primary completion
- Jun 30, 2014
- Completion
- Jun 30, 2014
- Last update posted
- Nov 19, 2015
2013 – 2014
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Vertex Investigational Site | Upland | California | — | — |
| Vertex Investigational Site | Fort Lauderdale | Florida | — | — |
| Vertex Investigational Site | Venice | Florida | — | — |
| Vertex Investigational Site | West Palm Beach | Florida | — | — |
| Vertex Investigational Site | Canton | Georgia | — | — |
| Vertex Investigational Site | Decatur | Georgia | — | — |
| Vertex Investigational Site | Elizabethtown | Kentucky | — | — |
| Vertex Investigational Site | Fredrick | Maryland | — | — |
| Vertex Investigational Site | Lincoln | Nebraska | — | — |
| Vertex Investigational Site | Rochester | New York | — | — |
| Vertex Investigational Site | Greensboro | North Carolina | — | — |
| Vertex Investigational Site | Duncansville | Pennsylvania | — | — |
| Vertex Investigational Site | Charleston | South Carolina | — | — |
| Vertex Investigational Site | Memphis | Tennessee | — | — |
| Vertex Investigational Site | Katy | Texas | — | — |
| Vertex Investigational Site | San Antonio | Texas | — | — |
| Vertex Investigational Site | Webster | Texas | — | — |
| Vertex Investigational Site | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01830985, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2015 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01830985 live on ClinicalTrials.gov.